Overview |
bs-1066R-Cy3 |
NME1 Polyclonal Antibody, Cy3 Conjugated |
WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human, Mouse, Rat |
Dog, Cow, Pig, Horse, Rabbit |
Specifications |
Cy3 |
Rabbit |
KLH conjugated synthetic peptide derived from human Nm23-H1 |
41-152/152 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
4830 |
P15531 |
Nucleus |
Nucleoside diphosphate kinase A; NME1; NDP kinase A; NDK A; NM23-H1A; NM23-H1B; NM23-LV; Granzyme A-activated DNase; GAAD; Metastasis inhibition factor nm23; Tumor metastatic process-associated protein; NDPKA; NM23A; |
NME1 plays a major role in the synthesis of nucleoside triphosphates other than ATP. Possesses nucleoside-diphosphate kinase, serine/threonine-specific protein kinase, geranyl and farnesyl pyrophosphate kinase, histidine protein kinase and 3'-5' exonuclease activities. Involved in cell proliferation, differentiation and development, signal transduction, G protein-coupled receptor endocytosis, and gene expression. Required for neural development including neural patterning and cell fate determination. Has tumor metastasis-suppressive capacity. |
Application Dilution |
WB |
1:300-5000 |
FCM |
1:20-100 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |